Publications by authors named "P L Ladaique"
In an ineffective transfusion context, solid-phase immunoassays using the Luminex platform for the detection and characterization of HLA antibodies are currently used to select HLA-compatible platelet products. A new HLA antibody identification method, the HISTO SPOT® HLA AB test (BAG Health care GmbH, Lich, Germany), based on the detection of antibodies directed against a recombinant single antigen (SA) by colored spots detected by HISTO MATCH HLA AB module software, runs fully automated on the MR.SPOT®.
View Article and Find Full Text PDFArticle Synopsis
- The INTERCEPT Blood System has been utilized in France for three years to reduce pathogen load in platelet concentrates, specifically for patients with acute myeloid leukemia (AML).
- A study on 176 patients compared the effectiveness of pathogen-reduced platelets (PR_PLT) versus untreated platelet products (U_PLT) in preventing bleeding and assessed transfusion efficiency through 24-hour corrected count increment (24h_CCI) and the time to the next transfusion.
- Results showed that higher doses of PR_PLT (>0.65×10/10 kg) led to similar 24h_CCI compared to U_PLT, facilitating transfusions every 48 hours, while lower doses were less effective in managing bleeding, highlighting
Importance: Pathogen reduction of platelet concentrates may reduce transfusion-transmitted infections but is associated with qualitative impairment, which could have clinical significance with regard to platelet hemostatic capacity.
Objective: To compare the effectiveness of platelets in additive solution treated with amotosalen-UV-A vs untreated platelets in plasma or in additive solution in patients with thrombocytopenia and hematologic malignancies.
Design, Setting, And Participants: The Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) study was a randomized, noninferiority, 3-arm clinical trial performed from May 16, 2013, through January 21, 2016, at 13 French tertiary university hospitals.
[Managing of platelet transfusion refractoriness of haematological malignancies. Experience IPC-EFSAM].
Transfus Clin Biol
November 2014
The platelet refractoriness is a complication of transfusion treatments potentially dramatic in onco-haematology. Chemo-treatment of haematological malignancies or packs of allogeneic bone marrow transplants require iterative platelet transfusion requirements. The discovery of a platelet refractoriness along with its support should be the most reactive as possible but also adapted to the cause.
View Article and Find Full Text PDF